A mathematical model for pancreatic cancer growth and treatments

Journal of Theoretical Biology

Volumn 351, Issue , 2014, Pages 74-82

  Louzoun, Yoram ^a   Xue, Chuan ^b   Lesinski, Gregory B ^b   Friedman, Avner ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Immune response; Immunotherapy; Pancreatic cancer

Indexed keywords

COLONY STIMULATING FACTOR 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA;

CANCER; GROWTH RATE; IMMUNITY; MATHEMATICAL ANALYSIS; NUMERICAL MODEL; QUALITATIVE ANALYSIS;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DEATH; CELL DENSITY; CELL PROLIFERATION; CELLULAR IMMUNITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GROWTH RATE; IMMUNE EVASION; IMMUNE STATUS; MACROPHAGE; MATHEMATICAL MODEL; PANCREAS CANCER; POLARIZATION; PRIORITY JOURNAL; SIMULATION; SUPPRESSOR CELL; SURVIVAL TIME; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; GENE SILENCING; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; PROGNOSIS; TUMOR ESCAPE;

CELL PROLIFERATION; GENE SILENCING; HUMANS; IMMUNOTHERAPY; MODELS, IMMUNOLOGICAL; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE;

EID: 84897857675     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2014.02.028     Document Type: Article

References (46)

1. Apte M.V., Haber P.S., Darby S.J., Rodgers S.C., McCaughan G.W., Korsten M.A., Pirola R.C., Wilson J.S. Pancreatic stellate cells are activated by proinflammatory cytokines. implications for pancreatic fibrogenesis. Gut 1999, 44:534-541.
2. Bachem M.G., Zhou S., Buck K., Schneiderhan W., Siech M. Pancreatic stellate cells - role in pancreas cancer. Langenbecks Arch. Surg. 2008, 393:891-900.
3. Bayne L.J., Beatty G.L., Jhala N., Clark C.E., Rhim A.D., Stanger B.Z., Vonderheide R.H. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012, 21:822-835.
4. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., Huhn R.D., Song W., Li D., Sharp L.L., Torigian D.A., O'Dwyer P.J., Vonderheide R.H. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
5. Bekaii-Saab T., Goldberg R.M. Folfirinox in locally advanced pancreas adenocarcinoma. back to the future?. Oncologist 2013, 18:487-489.
6. Bunt S.K., Clements V.K., Hanson E.M., Sinha P., Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through toll-like receptor 4. J. Leukoc. Biol. 2009, 85:996-1004.
7. Burris H., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
8. Corbo V., Tortora G., Scarpa A. Molecular pathology of pancreatic cancer. from bench-to-bedside translation. Curr. Drug Targ. 2012, 13:744-752.
9. Day J., Friedman A., Schlesinger L.S. Modeling the immune rheostat of macrophages in the lung in response to infection. Proc. Natl. Acad. Sci. USA 2009, 106:11246-11251.
10. de Pillis, L., Gallegos, A., Radunskaya, A., 2013. A model of dendritic cell therapy for melanoma. Front Oncol. 3. http://dx.doi.org/10.3389/fonc.2013.00056.
11. de Pillis L.G., Gu W., Radunskaya A.E. Mixed immunotherapy and chemotherapy of tumors. modeling applications and biological interpretations. J. Theor. Biol. 2006, 238:841-862. 10.1016/j.jtbi.2005.06.037.
12. de Pillis L.G., Radunskaya A.E., Wiseman C.L. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 2005, 65:7950-7958. 10.1158/0008-5472.CAN-05-0564.
13. Deharvengt S., Marmarelis M., Korc M. Concomitant targeting of EGF receptor, TGF-beta and SRC points to a novel therapeutic approach in pancreatic cancer. PLoS One 2012, 7:e39684.
14. Ellermeier J., Wei J., Duewell P., Hoves S., Stieg M.R., Adunka T., Noerenberg D., Anders H.J., Mayr D., Poeck H., Hartmann G., Endres S., Schnurr M. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res. 2013, 73:1709-1720.
15. Feig C., Gopinathan A., Neesse A., Chan D.S., Cook N., Tuveson D.A. The pancreas cancer microenvironment. Clin. Cancer Res. 2012, 18:4266-4276.
16. Fukunaga A., Miyamoto M., Cho Y., Murakami S., Kawarada Y., Oshikiri T., Kato K., Kurokawa T., Suzuoki M., Nakakubo Y., et al. Cd8+ tumor-infiltrating lymphocytes together with cd4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004, 28:e26-e31.
17. Galante A., Tamada K., Levy D. B7-h1 and a mathematical model for cytotoxic T cell and tumor cell interaction. Bull. Math. Biol. 2012, 74:91-102. 10.1007/s11538-011-9665-1.
18. Gaspar N.J., Li L., Kapoun A.M., Medicherla S., Reddy M., Li G., O'Young G., Quon D., Henson M., Damm D.L., Muiru G.T., Murphy A., Higgins L.S., Chakravarty S., Wong D.H. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Mol. Pharmacol. 2007, 72:152-161.
19. Gnerlich J.L., Mitchem J.B., Weir J.S., Sankpal N.V., Kashiwagi H., Belt B.A., Porembka M.R., Herndon J.M., Eberlein T.J., Goedegebuure P., Linehan D.C. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J. Immunol. 2010, 185:4063-4071.
20. Guiot C., Delsanto P.P., Carpinteri A., Pugno N., Mansury Y., Deisboeck T.S. The dynamic evolution of the power exponent in a universal growth model of tumors. J. Theor. Biol. 2006, 240:459-463.
21. Hackert T., BŸchler M.W. Pancreatic cancer. advances in treatment, results and limitations. Dig. Dis. 2013, 31:51-56.
22. Hariharan, D., Saied, A., Kocher, H.M., 2008. Analysis of Mortality Rates for Pancreatic Cancer Across the World, vol. 10. HPB, Oxford, pp. 58-62.
23. Heinemann V., Reni M., Ychou M., Richel D.J., Macarulla T., Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat. Rev. 2013, 40:118-128.
24. Hosein P.J., de Lima Lopes G., Pastorini V.H., Gomez C., Macintyre J., Zayas G., Reis I., Montero A.J., Merchan J.R., RochaLima C.M. A phase ii trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am. J. Clin. Oncol. 2013, 36:151-156.
25. Itakura E., Huang R.R., Wen D.R., Paul E., WŸnsch P.H., Cochran A.J. Il-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod. Pathol. 2011, 24:801-809.
26. Koido S., Homma S., Takahara A., Namiki Y., Tsukinaga S., Mitobe J., Odahara S., Yukawa T., Matsudaira H., Nagatsuma K., Uchiyama K., Satoh K., Ito M., Komita H., Arakawa H., Ohkusa T., Gong J., Tajiri H. Current immunotherapeutic approaches in pancreatic cancer. Clin. Dev. Immunol. 2011, 2011:267-539.
27. Korc M. Role of growth factors in pancreatic cancer. Surg. Oncol. Clin. N. Am. 1998, 7:25-41.
28. Kurahara H., Shinchi H., Mataki Y., Maemura K., Noma H., Kubo F., Sakoda M., Ueno S., Natsugoe S., Takao S. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 2011, 167:e211-e219.
29. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., Drebin J.A., Strasberg S.M., Eberlein T.J., Goedegebuure P.S., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 2002, 169:2756-2761.
30. Mace T.A., Ameen Z., Collins A., Wojcik S.E., Mair M., Young G.S., Fuchs J.R., Eubank T.D., Frankel W.L., Bekaii-Saab T., Bloomston M., Lesinski G.B. Pancreatic cancer associated stellate cells promote differentiation of myeloid-derived suppressor cells in a stat3-dependent manner. Cancer Res. 2013, 73:3007-3018.
31. Omary M.B., Lugea A., Lowe A.W., Pandol S.J. The pancreatic stellate cell. a star on the rise in pancreatic diseases. J. Clin. Invest. 2007, 117:50-59.
32. Phillips, P., 2012. Pancreatic cancer and tumor microenvironment. In: Transworld Research Network. Pancreatic Stellate Cells and Fibrosis. Trivandrum, India.
33. Pylayeva-Gupta Y., Lee K.E., Hajdu C.H., Miller G., Bar-Sagi D. Oncogenic kras-induced gm-csf production promotes the development of pancreatic neoplasia. Cancer Cell 2012, 21:836-847.
34. Radunskaya, A., Hook, S., 2012. Modeling the kinetics of the immune response, in: New Challenges for Cancer Systems Biomedicine. Springer Milan, pp. 267-282.
35. Robertson-Tessi M., El-Kareh A., Goriely A. A mathematical model of tumor-immune interactions. J. Theor. Biol. 2012, 294:56-73.
36. Roshani R., McCarthy F., Hagemann T. Inflammatory cytokines in human pancreatic cancer. Cancer Lett. 2014, 345:157-163.
37. Ryschich E., Notzel T., Hinz U., Autschbach F., Ferguson J., Simon I., Weitz J., Frohlich B., Klar E., Buchler M.W., et al. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin. Cancer Res. 2005, 11:498-504.
38. Seki N., Brooks A.D., Carter C.R.D., Back T.C., Parsoneault E.M., Smyth M.J., Wiltrout R.H., Sayers T.J. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J. Immunol. 2002, 168:3484-3492.
39. Shek F.W.T., Benyon R.C., Walker F.M., McCrudden P.R., Pender S.L.F., Williams E.J., Johnson P.A., Johnson C.D., Bateman A.C., Fine D.R., Iredale J.P. Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis. Am. J. Pathol. 2002, 160:1787-1798.
40. Sichert D., Aust D., Langer S., Baretton G., Dieter P. Characterization of macrophage subpopulations and microvessel density in carcinomas of the gastrointestinal tract. Anticancer Res. 2007, 27:1693-1700.
41. Steer H.J., Lake R.A., Nowak A.K., Robinson B.W.S. Harnessing the immune response to treat cancer. Oncogene 2010, 29:6301-6313.
42. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., Yokoyama W.M., Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
43. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., Korn R.L., Desai N., Trieu V., Iglesias J.L., Zhang H., Soon-Shiong P., Shi T., Rajeshkumar N.V., Maitra A., Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer. a phase I/II trial. J. Clin. Oncol. 2011, 29:4548-4554.
44. Wang R., Lu M., Zhang J., Chen S., Luo X., Qin Y., Chen H. Increased il-10 MRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J. Exp. Clin. Cancer Res. 2011, 30:62.
45. West G.B., Brown J.H., Enquist B.J. A general model for ontogenetic growth. Nature 2001, 413:628-631.
46. Wilson S., Levy D. A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy. Bull. Math. Biol. 2012, 74:1485-1500. 10.1007/s11538-012-9722-4.